
August 05, 2024
BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological disorders, is pleased to announce a new study to run in partnership with Monash University. The study will evaluate BlinkLab as a medical device able to monitor the therapeutic effects of ketamine on cognitive processes whereby sensory information is converted into decision making. In the future, results from this study can help facilitate cognitive behavioural therapy outcomes in patients with psychiatric conditions such as depression, schizophrenia, epilepsy, and post-traumatic stress disorder (PTSD).
Highlights
- Study provides a unique opportunity to discover the building blocks of cognition with the potential to transform our understanding of a range of clinical conditions including depression, schizophrenia, epilepsy, PTSD.
- Potential to demonstrate that drugs targeting glutamatergic neurotransmission can treat some aspects of psychiatric disease symptomology or improve the efficacy of cognitive behavioural therapy.
- Evaluates ability of BlinkLab tests to be used as a tool to measure pharmacological effects of existing and novel therapeutic agents.
Significance of the Study
Perceptual decision-making is a fundamental cognitive process where sensory information is transformed into meaningful interpretations of the environment, guiding our actions. This field has flourished through the integration of neuroscience and mathematical modelling , providing a robust framework for investigating the neural mechanisms involved. The core idea is that decisions are based on the accumulation of sensory evidence until a decision threshold is reached. These advancements offer a unique opportunity to uncover the fundamental components of cognition and have the potential to revolutionise our understanding of various clinical conditions. By characterising underlying mechanistic abnormalities, refining clinical classifications, and identifying intervention targets, this research holds promise for significant clinical advancements and new therapies for a variety of psychiatric and neurodevelopmental conditions.
The study, conducted by the School of Psychological Sciences at Monash University will investigate the impact of glutamate challenge on perceptual decision making (including behavioural performance, sensorimotor gating) by administering ketamine while participants perform a prepulse inhibition test using BlinkLab application.
The study will be able to demonstrate whether administration of ketamine can disrupt basic sensory encoding mechanisms, which will be detectable in reduced prepulse inhibition.
Study Design
The study will recruit up to 35 healthy adults between 18-55 years old. Each participant will complete 3 testing sessions after ketamine administration. Their participation is expected to take 4-5 weeks per subject.
Terms of the Collaboration Agreement (“Agreement”)
- Responsibilities: BlinkLab will provide access to its technology, data and shall facilitate the use of its platform during the term of the Agreement.
- Financial arrangements: None at the date of signing (to be determined via mutual agreement in the future and in a separate agreement).
- Intellectual Property: Each party will retain all right, title and interest in and to its background intellectual property (copyright, trademarks, designs, know how, patents, plant varieties, confidential information and all other intellectual property as defined in article 2 of the Convention establishing the World Intellectual Property Organization 1967). Any project IP (generated through the study) will be owned by Monash University.
- Term: Date of signature by the last party to sign (5 August 2024), until completion of the Research Project as communicated by Monash.
- Termination: Either party may terminate this Agreement by giving between 5 and 20 days written notice (at the terminating party’s election) to the other party if the other party commits a material breach of the Agreement and does not remedy that breach within 10 days after receiving notice requiring them to do so. Monash may terminate this agreement with immediate effect by giving written notice to BlinkLab.
- Confidentiality: Standard confidentiality terms for an agreement of this nature included.
This announcement has been approved by the Board of Directors.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
BB1:AU
The Conversation (0)
25 September 2024
BlinkLab Limited
Revolutionising Mental Health Care Through Mobile Solutions
Revolutionising Mental Health Care Through Mobile Solutions Keep Reading...
01 May
Successful Placement of A$7.66M to Underpin Growth Strategy
BlinkLab Limited (BB1:AU) has announced Successful Placement of A$7.66M to Underpin Growth StrategyDownload the PDF here. Keep Reading...
29 April
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 April
Quarterly Activities/Appendix 4C Cash Flow Report
BlinkLab Limited (BB1:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
31 March
BlinkLab Surpasses Key Milestone in Pivotal U.S. Trial
BlinkLab Limited (BB1:AU) has announced BlinkLab Surpasses Key Milestone in Pivotal U.S. TrialDownload the PDF here. Keep Reading...
30 March
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
10h
Chevron Extends Partnership with REM in Major Contract Award
RemSense Technologies (REM:AU) has announced Chevron Extends Partnership with REM in Major Contract AwardDownload the PDF here. Keep Reading...
17 October
Tech Weekly: Broadcom and OpenAI Sign Deal, AMD and Oracle Announce Partnership
This week was marked by strong, event-driven volatility across the tech sector. Market moves were shaped by artificial intelligence (AI) infrastructure announcements, semiconductor earnings, signals of macroeconomic stress and escalating tensions between the US and China. Effects of the US... Keep Reading...
16 October
AF2 Capital Corp. Enters into Letter of Intent for Reverse-Takeover Transaction with EverKind Inc.
AF2 Capital Corp. (TSXV: AF.P) ("AF2" or the "Company") is pleased to announce it has entered into a non-binding letter of intent dated October 14, 2025 (the "LOI") with EverKind Inc. ("EverKind"), an AI-powered emotional wellness platform, which sets forth, in general terms, the basic terms and... Keep Reading...
08 October
AI Market Update: Q3 2025 in Review
Q3 solidified artificial intelligence (AI) as the central growth engine within the tech sector, driving the Nasdaq Composite (INDEXNASDAQ:.IXIC) and S&P 500 (INDEXSP:.INX) to new heights. AI-focused stocks dominated market gains during the period, while venture capital funding for AI startups in... Keep Reading...
26 September
Tech Weekly: Tech Stocks React to Fed, AI News and Geopolitical Tensions
This week’s market action reflected renewed caution amid evolving signals from the US Federal Reserve, with tech stocks facing pressure from shifting interest rate expectations and renewed overvaluation concerns. Artificial intelligence (AI) heavyweight NVIDIA (NASDAQ:NVDA) announced a US$100... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00






